Synbiotic to improve gut barrier and microbiota in middle-aged and older adults with excess weight
Official title: The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals: a Randomized, Double-blind, Placebo-controlled Study
Run by Novonesis · NCT07453823 · Data updated 2026-11-12
This study will test whether a synbiotic (two probiotic strains plus a prebiotic) can improve gut barrier function, shift gut bacteria, and reduce gastrointestinal discomfort in people aged 50–70 with BMI 25–35 and mild bowel symptoms.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 70 Years |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Novonesis Industry-sponsored |
| Locations | 1 site (Cork, Blackpool) |
| Status | Recruiting |
| Started | March 18, 2026 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT07453823 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50–70 with BMI 25.0–35.0 kg/m² who report mild-to-moderate GI complaints (GSRS-IBS score 20–45) and low bowel frequency during the run-in period are ideal candidates.
✕Probably not a fit
People outside the 50–70 age or BMI 25–35 range, those without the specified symptom profile or bowel-frequency criteria, or those with significant gastrointestinal disease or recent interfering treatments are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled intervention with an 8-week daily synbiotic or placebo period followed by a 2-week follow-up. Participants complete a run-in diary to confirm symptom levels and bowel frequency before randomization. Outcomes include measures of intestinal permeability and integrity, changes in gut microbiota composition, and patient-reported gastrointestinal symptoms. The trial enrolls middle-aged to elderly adults with overweight and mild-to-moderate GI complaints and low bowel frequency.
Why it matters
Potential benefit: If successful, the synbiotic could reduce gastrointestinal discomfort and improve markers of gut barrier integrity and microbial balance in the target group.
How similar studies have gone: Previous synbiotic and probiotic studies have shown mixed but sometimes promising effects on microbiota composition and modest improvements in permeability or symptoms in selected populations.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Be able to give informed consent. 2. Be between 45 to 70 years of age (inclusive). 3. BMI \<40.0 kg/m² 4. Willing to maintain current level of physical activity and diet during the participation in the study. 5. Experience ≤4 bowel movements per week within the month prior to screening 6. Participants reported subclinical mild to moderate gastrointestinal complaints as defined by GSRS-IBS score 20-52 at screening. 7. Willing to consume the study product daily for the duration of the study. 8. Willing to eat the same meal the evening before visiting site (visit 2 to visit 5). Participants are eligible for randomization if they fulfill the following two criteria based on the diary recordings during the run-in period prior to visit 2 9. Average GSRS-IBS composite symptom score between 20-52 during the two-week run-in period Record ≤8 bowel movements in the daily diary during the two-week run-in period Exclusion Criteria: 1. Has a history of drug and/or alcohol abuse. 2. Has food allergies, or other issues with foods, that would preclude intake of the study products. 3. Smoking, chewable tobacco and/or vaping and/or use of other nicotine products. 4. Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Excluded health conditions include: 1. diagnosis of GI disease (e.g. gastric or duodenal ulcers, inflammatory bowel disease, colon cancer) or irritable bowel syndrome (IBS) 2. GI surgery that might have an effect on gastrointestinal tract function except cholecystectomy and appendectomy in the past 5 years or any major bowel resection at any time. 3. history of CVD 4. uncontrolled hypertension 5. Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Prohibited medications include: 1. systemic antimicrobial medication (including suppositories) within 4 weeks prior to visit 1 2. OTC medications, for digestive symptoms such as PPIs, anti-spasmodics, laxatives, anti-diarrheic drugs within 2 weeks prior to visit 1 10\. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study. 11\. Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results. c. immunosuppressant drugs within the 4 weeks prior to the visit 1 d. systemic steroids within the 4 weeks prior to the visit 1 6. Regular oral non-steroidal anti-inflammatory (NSAIDs) within 1 week prior to visit 1 (topical NSAIDS allowed, Low-dose prophylactic aspirin use is acceptable if stable for 3 months prior to screening.) 7. Current or recent (in the past 4 weeks prior to visit 1) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results, including: a. Herbal supplements for digestive symptoms b. Large doses of vitamins and minerals, unless in stable dose c. Probiotic supplements d. Iron supplements 8. Current or recent (in the past 2-weeks) use of prohibited foods including yoghurts containing probiotics. 9\. Planned major changes in lifestyle \[i.e., diet (e.g. start of fibre-enriched diet), dieting, exercise level, travelling\] during the duration of the study.
Where it's running
-
Atlantia Clinical Trials Ltd
Cork, Blackpool, Ireland Recruiting
Study contacts
- Principal investigator: Martin Buckley, Professor — Atlantia Clinical Trials Ltd
- Study coordinator: Sara Engel, PhD
- Email: saen@novonesis.com
- Phone: +45 45 74 74 74
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mediterranean diet and processed food in adults with celiac disease on a gluten-free diet
This observational study looks at whether following a Mediterranean-style diet or eating more highly processed foods affects GI symptoms and quality of life in adults with celiac disease who have been on a strict gluten-free diet.
-
Fiber supplement for digestive symptoms in endometriosis
A fiber-based supplement is being tested to see if it is safe and helps with gut and vaginal microbiomes and digestive symptoms in women with endometriosis.
-
IgG Binding Protein LT for gut health during travel
This study tests whether IgG Binding Protein LT helps healthy adults maintain gut health while traveling internationally.
-
Phage-based approach to support gut and skin health
Two bacteriophage treatments are tested over 4 weeks to see if they improve gut and skin health in adults with mild to moderate GI symptoms.
-
Effects of Music Therapy, Breathing Exercises, and Virtual Reality on Recovery After Cesarean
This study tests whether music therapy, breathing exercises, and virtual reality help women recover after a cesarean section.
-
8-week daily supplement program to support gut and digestive health
This 8-week test will see if taking a daily two-product dietary supplement system helps adults with self-reported digestive symptoms improve stool-based biomarkers and their symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.